Amyris Prices $600.0 Million Of 1.50% Convertible Senior Notes Due 2026

EMERYVILLE, Calif., Nov. 10, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced that it has priced $600.0 million aggregate principal amount of 1.50% convertible senior notes due 2026 (the "notes"). The size of the offering was increased from the previously announced $400.0 million in aggregate principal amount. The notes are to be offered and sold in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Act"). Amyris also granted the initial purchasers of the notes an option to purchase, within a 13-day period from, and including the date on which the notes are first issued, up to an additional $90.0 million aggregate principal amount of notes. The sale is expected to close on November 15, 2021, subject to customary closing conditions.